Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune signature profiling study in resectable non-squamous NSCLC treated with neoadjuvant atezolizumab plus carboplatin and nab-paclitaxel
2020-000388-21Phase 2Active
- Sponsor
- Heidelberg University
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin and nab-paclitaxel in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Heidelberg University. Primary endpoint: Major pathologic response rate. Started Oct 2020; status: active.
02
Drugs
atezolizumabcarboplatinnab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2020-000388-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000388-21.